Morco (Fluticasone Furoate)

Fluticasone furoate binds to glucocorticoid receptors in the cells lining the nasal passages. This interaction modifies gene expression, decreasing the release of inflammatory mediators such as cytokines and chemokines, which in turn reduces swelling and mucus production in the nasal mucosa.

The prescribed dose of Morco is determined by the treating clinician based on the patient’s age, severity of symptoms, and response to therapy. Patients should follow the specific instructions provided by their healthcare professional and the product labeling.

Safety data for fluticasone furoate in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Morco.

To request Morco, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Morco (fluticasone furoate) is a once‑daily, high‑potency nasal corticosteroid. Compared with older agents such as fluticasone propionate or budesonide, fluticasone furoate offers a longer residence time on the nasal mucosa, allowing effective symptom control with a single daily spray.

Morco should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, excessive heat, and direct sunlight. Do not freeze the spray, and ensure the cap is tightly closed when not in use.

Morco is administered as a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and spray the prescribed number of sprays while breathing in gently. The process is repeated in the other nostril if directed by the prescriber.

Serious but rare risks include severe allergic reactions (anaphylaxis), vision problems such as cataract or glaucoma with long‑term use, and systemic adrenal suppression, especially when used at high doses or for extended periods. Patients should report any unusual symptoms to their healthcare provider promptly.

Morco is contraindicated in individuals with known hypersensitivity to fluticasone furoate or any component of the formulation. It should also be avoided in patients with active nasal infections (bacterial, fungal, or viral) unless directed by a physician, and in those for whom systemic corticosteroid exposure is contraindicated.